menu Home chevron_right
News

GOVERNMENT STRUGGLES TO MEET DEMAND FOR HIV PREVENTION INJECTION

newsroom-radiopacis | 19 November 2026

 

Twice a year HIVAIDS injectable drug

The demand for Lenacapavir, a long-acting HIV prevention injection administered twice a year, is putting pressure on the country’s limited supplies in Uganda and neighboring Kenya.

The Ministry of Health in Kampala confirmed that doses of the drug tend to get exhausted within days of reaching health facilities.

Dr Peter Mudiope, the Ministry of Health’s HIV Prevention Coordinator, says the response to the new prevention drug has exceeded initial expectations, with some people who previously declined other forms of pre-exposure prophylaxis (PrEP) now seeking the injection.

Speaking during a regional webinar on advancing access to Lenacapavir for PrEP in Kenya, Malawi and Uganda, Mudiope said the initial rollout exposed the need to balance demand creation with the availability of commodities.

“When we launched PrEP on April 17 this year, we had only 20 doses for the site, and they got finished. Yet we had to reserve the doses for the next six months. We had to call the hospital to come to the launch place. That’s when we realised that we had to promote it as an option, not as LEN,” Mudiope said.

He explained that the Ministry initially expected the new injection to attract people already using oral PrEP who wanted a more convenient alternative.

However, the experience has shown that the new product is also attracting people who had previously not considered HIV prevention medication.

“Our initial assumption was to switch people from oral PrEP to LEN, those who were willing. But we realised that some people are not willing to leave oral PrEP. So we have to respect that in the demand generation. But also, the demand generation has created an opportunity for people who are not willing to use any form of PrEP because of the new choice. We are seeing that there are many more new users of PrEP in the country,” he said.

Mudiope, an acclaimed researcher on prevention, said Uganda currently has 103 facilities providing Lenacapavir and is expecting additional supplies in December as the Ministry prepares to expand access to more health facilities.

He acknowledged that the demand remains high, particularly among people who prefer the six-monthly injection to other available prevention methods.

“We are having a lot of requests for initiation. We are having more doses coming in December, and we are preparing for additional sites. We are managing the demand, first of all, by prioritising the regions and facilities that have very high populations of people taking up oral PrEP,” he said.

The Ministry is encouraging people to continue using other available PrEP options as it works to increase supplies.

These include daily oral PrEP, the dapivirine vaginal ring and injectable cabotegravir, which is administered every two months.

However, Mudiope noted that some health workers and clients consider Lenacapavir more convenient, complicating efforts to maintain interest in the other prevention options.

He said the country was also considering how to position the different long-acting products within its prevention programme, including whether to retain cabotegravir alongside Lenacapavir or reserve it for particular circumstances.

Mwehonge Kenneth, Executive Director of HEPS Uganda, says the introduction of Lenacapavir requires more than public awareness campaigns.

He urged more investment in community structures that can provide accurate information, address stigma and misinformation, and link interested people to health facilities.

Under the project, HEPS worked with communities, local governments and health facilities to identify and train 246 community resource persons drawn from 115 PrEP implementation sites.

The project also trained 27 national trainers, including personnel from the Ministry of Health. Mwehonge said the community-led approach relied on people already trusted within their communities rather than establishing parallel structures.

“Communities believe in their peers, and those are the ones, once equipped with the right information, who support in addressing stigma and misinformation. So it has to be a trusted voice within the community,” he said.

The community resource persons were equipped with referral forms to link people interested in PrEP to health facilities. They also collected feedback, including information on how clients responded to the different prevention products.

Mwehonge said the project deliberately promoted a range of HIV prevention options rather than presenting Lenacapavir as a replacement for existing methods.

“Keeping prevention as a choice is important. We are not only promoting one product, but we are promoting several, all available proven products alongside LEN, which is the newest baby. But we promoted choice,” he said.

The project also supported the revision of Uganda’s PrEP communication strategy to incorporate Lenacapavir alongside other prevention products. The Ministry of Health’s communication department reviewed the materials before they were submitted to the Uganda AIDS Commission for clearance.

Mwehonge revealed that one of the lasting lessons is that community mobilisation should be integrated into existing health structures to ensure continuity after short-term donor-supported projects end.

“The community health workforce that we supported is attached to these facilities, and that’s a sustainable way of keeping them engaged. So my overall lesson is working within the system and not duplicating it,” he said.

Patricia Jeckonia , Programme Manager for Policy, Advocacy and HIV Prevention at LVCT Health in Kenya, says the experience in Kenya demonstrates how supply shortages can undermine community confidence when people are mobilised to seek a product that is not consistently available.

Kenya deliberately developed its communication campaign around PrEP choice, rather than concentrating on Lenacapavir, after observing that the introduction of newer products was affecting the uptake of oral PrEP and leaving some people unaware of other prevention options.

Jeckonia said the project found that even where several products were available, communities did not necessarily have sufficient information to make informed decisions.

“When we were starting the CASPER project, Kenya had already rolled out Lenacapavir, and so we were already starting to see a decrease in uptake of oral PrEP. We rolled out Lenacapavir at the same time as CAB-LA, and people seemed not to know anything about CAB-LA. Also, we had a few facilities that had a dapivirine ring, and again, a number of people were not even aware of it,” she said.

She said the project therefore used the available resources to increase awareness of all prevention options, including condoms, rather than allowing one product to dominate public communication.

The Kenyan programme involved co-creating messages with adolescent girls and young women, pregnant and breastfeeding women, adolescent boys and young men and other priority populations. It also recruited social media influencers identified by the target communities as people whose messages they trusted.

However, Jeckonia said the rapid exhaustion of Lenacapavir supplies has created difficulties in managing expectations, with some people arriving at facilities only to find that the drug is unavailable.

“Every time you had LEN in a facility, it would take two to three days, and it’s over. So that continued. But our demand generation was also very targeted to the counties that were prioritised and around facilities that were providing PrEP choice,” she said.

She added that the shortages have forced health officials to reconsider how they communicate availability and support clients who arrive at facilities seeking a particular product.

“Because Lenacapavir would run out very, very quickly, it’s been a bit difficult even just managing that community trust. They keep telling you, you told us these products are here, but we are coming, and we cannot find them,” Jakonaya said.

She said Kenya’s experience demonstrates the importance of communicating supply interruptions quickly and helping health workers explain alternative prevention options to clients.

“Even when there is not yet enough supply, it is very important to empower communities with the right information so that they are aware of what’s available. We give all of the information, but inform them that their supply is not yet enough for now. It’s being rolled out. However, we are also promoting the other options,” she said.

Jakonaya also called for demand generation to be incorporated into planning from the beginning of a product’s introduction, rather than treated as an activity that follows its launch.

“Demand generation should not be an afterthought. It should be at the very beginning when we are thinking about availability of the product. We should be thinking about how people will know and invest in it,” she said.

The webinar, convened under the Advancing Access to LEN for PrEP initiative, brought together implementing partners and government officials from Uganda, Kenya and Malawi to share experiences in preparing communities for the introduction of the new HIV prevention technology.

Warren Mitchell, the executive director of AVAC,  a leading global HIV prevention advocate who has spoken extensively on the rollout, funding challenges, and potential of lenacapavir, said the initiative was designed to examine how governments, communities and implementing partners could work together to support access and uptake of new prevention options.

“We’ve been working with three partners in Kenya, Malawi and Uganda, and these have partnered closely with the ministries of health to test practical approaches to demand generation and community engagement. And today we’ll hear what they have tried, what they have learned, and what those lessons mean for scale-up,” Mitchell said.

The three countries reported similar experiences, particularly the importance of developing communication materials with communities, using trusted local voices and integrating the new injection into broader HIV prevention programmes.

In Malawi, Simon Sikwese, Executive Director of Pokachere, said the country adopted a phased approach to distributing communication materials to avoid generating demand in districts where Lenacapavir was not yet available.

He cautioned that awareness campaigns must be coordinated with the capacity of health facilities to provide the product.

“Ensure that you don’t create demand that you cannot meet. You must look at, for example, in the case of Lenacapavir, how much Lenacapavir you are receiving and how much demand you should create to make sure that you are not exciting people and then, in the end, they don’t access the Lenacapavir,” Sikwese said.

The experience is particularly relevant as Uganda prepares to expand the rollout.

The Ministry’s original plan was to increase the number of facilities offering Lenacapavir from 103 to 300 by December 2026.

The challenge will be sustaining the community confidence generated by the introduction while ensuring that procurement and distribution arrangements keep pace with demand. Fortunately. there are reports that generic version of Lenacapir will be available on the market at a lower price compared t the branded one.

Dr. Mudiope said the experience also presents an opportunity for countries to share lessons and develop common approaches to communicating new prevention choices.

He called for the three countries to develop a communication toolkit that could be adapted and used by other countries introducing Lenacapavir.

 

Written by newsroom-radiopacis

Comments

This post currently has no comments.

Leave a Reply






  • cover play_circle_filled

    90.9 FM
    Radio Pacis Arua 90.9 FM

  • cover play_circle_filled

    94.5 FM
    Radio Pacis Arua 94.5 FM

  • cover play_circle_filled

    101.4 FM
    Radio Pacis Gulu 101.4 FM

  • cover play_circle_filled

    104.8 FM
    Radio Pacis Moyo 104.8 FM

play_arrow skip_previous skip_next volume_down
playlist_play